Benefits of conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in pediatric renal transplant patients with stable graft function

Pediatric Transplantation

Volumn 13, Issue 2, 2009, Pages 188-193

  De Paula Meneses, Rejane ^a   Halusch Kotsifas, Cecília ^a  

^a HOSPITAL PEQUENO PRÍNCIPE   (Brazil)

Author keywords

CellCept; Conversion; Enteric coated; Mycophenolate mofetil; Mycophenolic acid; Myfortic; Paediatric

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN A; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY;

ABDOMINAL PAIN; ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CORTICOSTEROID THERAPY; DIARRHEA; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENTERIC COATED TABLET; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; HUMAN TISSUE; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; MALE; NAUSEA; PATIENT COMPLIANCE; PROSPECTIVE STUDY; UNSPECIFIED SIDE EFFECT; VOMITING;

ADOLESCENT; CHILD; FEMALE; GLOMERULAR FILTRATION RATE; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MYCOPHENOLIC ACID; PROSPECTIVE STUDIES; TABLETS, ENTERIC-COATED; TREATMENT OUTCOME;

EID: 59449095440     PISSN: 13973142     EISSN: 13993046     Source Type: Journal    
DOI: 10.1111/j.1399-3046.2008.00977.x     Document Type: Article

References (33)

1. Sollinger HW. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. US Renal Transplant Mycophenolate Mofetil Study Group. Transplantation 1995 : 60 : 225 232.
2. European Mycophenolate Mofetil Cooperative Study Group. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet 1995 : 345 : 1321 1325.
3. The tricontinental mycophenolate mofetil renal transplantation study group. A blinded, randomized, clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 1996 : 61 : 1029 1037.
4. Ojo A, Meier-Kriesche HU, Hanson JA, et al. Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection. Transplantation 2000 : 69 : 2405 2409.
5. Meier-Kriesche HU, Steffen BJ, Hochberg AM, et al. Mycophenolate mofetil versus azathioprine therapy is associated with a significant protection against long-term renal allograft function deterioration. Transplantation 2003 : 75 : 1341 1346.
6. Meier-Kriesche HU, Li S, Gruessner RW, et al. Immunosuppression: Evolution in practice and trends, 1994-2004. Am J Transplant 2006 : 6 : 1111 1131.
7. Ferraris JR, Ghezzi LF, Vallejo G, Piantanida JJ, Araujo JL, Sojo ET. Improved long-term allograft function in pediatric renal transplantation with mycophenolate mofetil. Pediatr Transplant 2005 : 9 : 178 182.
8. Benfield MR, Symons JM, Bynon S, et al. Mycophenolate mofetil in pediatric renal transplantation. Pediatr Transplant 1999 : 3 : 33 37.
9. Höcker B, Weber LT, Bunchman T, Rashford M, Tönshoff B Tricontinental MMF Suspension Study Group. Mycophenolate mofetil suspension in pediatric renal transplantation: Three-year data from the tricontinental trial. Pediatr Transplant 2005 : 9 : 504 511.
10. Benz K, Plank C, Griebel M, Montoya C, Dötsch J, Klare B. Mycophenolate mofetil introduction stabilizes and subsequent cyclosporine A reduction slightly improves kidney function in pediatric renal transplant patients: A retrospective analysis. Pediatr Transplant 2006 : 10 : 331 336.
11. David-Neto E, Araujo LM, Lemos FC, et al. Introduction of mycophenolate mofetil and cyclosporin reduction in children with chronic transplant nephropathy. Pediatr Transplant 2001 : 5 : 302 309.
12. Knoll GA, Macdonald I, Khan A, Van Walraven C. Mycophenolate mofetil dose reduction and the risk of acute rejection after renal transplantation. J Am Soc Nephrol 2003 : 14 : 2381 2386.
13. Pelletier RP, Akin B, Henry ML, Elkhammas EA, Rajab A, Ferguson RM. The impact of mycophenolate mofetil dosing patterns on clinical outcome after renal transplantation. Clin Transplant 2003 : 17 : 200 205.
14. Tierce JC, Porterfield-Baxa J, Petrilla AA, Kilburg A, Ferguson RM. Impact of mycophenolate mofetil (MMF)-related gastrointestinal complications and MMF dose alterations on transplant outcomes and healthcare costs in renal recipients. Clin Transplant 2005 : 19 : 779 784.
15. Bunnapradist S, Lentine KL, Burroughs TE, et al. Mycophenolate mofetil dose reductions and discontinuations after gastrointestinal complications are associated with renal transplant graft failure. Transplantation 2006 : 82 : 102 107.
16. Hardinger K, Brennan DC, Lowell J, Schnitzler M. Long-term outcome of gastrointestinal complications in renal transplant patients treated with mycophenolate mofetil. Transplant Int 2004 : 17 : 609 616.
17. Salvadori M, Holzer H, de Mattos A, et al. Enteric-coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novo renal transplant patients. Am J Transplant 2004 : 4 : 231 236.
18. Salvadori M, Holzer H, Civati G, et al. Long-term administration of enteric-coated mycophenolate sodium (EC-MPS, myfortic®) is safe in kidney transplant patients. Clin Nephrol 2006 : 66 : 112 119.
19. Budde K, Curtis J, Knoll G, et al. Enteric-coated mycophenolate sodium can be safety administered in maintenance renal transplant patients: Results of a 1-year study. Am J Transplant 2004 : 4 : 237 243.
20. Budde K, Knoll G, Curtis J, et al. Long-term safety and efficacy after conversion of maintenance renal transplant recipients from mycophenolate mofetil (MMF) to enteric-coated mycophenolate sodium (EC-MPS, myfortic®). Clin Nephrol 2006 : 66 : 103 111.
21. Abbud-Filho M, Girón F, Hernández EP, et al. Myproms latam study group. Stable renal transplant recipients can be safely converted from MMF to enteric-coated mycophenolate sodium tablets: Interim results of a multicenter Latin American study. Transplant Proc 2004 : 36 : 1647 1649.
22. Nashan B, Suwelack B, Ivens K, et al. Conversion to enteric-coated mycophenolate sodium from various doses of mycophenolate mofetil: Results of a prospective international multicenter trial in maintenance renal transplant patients receiving cyclosporine. Transplant Proc 2006 : 38 : 2856 2859.
23. Calvo N, Sanchez-Fructuoso AI, Conesa J, Moreno A, Barrientos A. Renal transplant patients with gastrointestinal intolerability to mycophenolate mofetil: Conversion to enteric-coated mycophenolate sodium. Transplant Proc 2006 : 38 : 2396 2397.
24. Arns W, Breuer S, Choudhury S, et al. Enteric-coated mycophenolate sodium delivers bioequivalent MPA exposure compared with mycophenolate mofetil. Clin Transplant 2005 : 19 : 199 206.
25. Chan L, Mulgaonkar S, Walker R, Arns W, Ambühl P, Schiavelli R. Patient-reported gastrointestinal symptom burden and health-related quality of life following conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium. Transplantation 2006 : 81 : 1290 1297.
26. Boswell A, Rigg K, Shehata M. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in patients with gastrointestinal side effects: Case studies. Prog Transplant 2006 : 16 : 138 140.
27. ®) in a patient at high immunological risk. Drugs 2006 : 66 (Suppl 2 25 27.
28. ®). Drugs 2006 : 66 (Suppl 2 9 10.
29. Roberti I, Reisman L. A comparative analysis of the use of mycophenolate mofetil in pediatric vs adult renal allograft recipients. Pediatr Transplant 1999 : 3 : 231 235.
30. Ettenger R, Bartosh S, Choi L, et al. Pharmacokinetics of enteric-coated mycophenolate sodium in stable pediatric renal transplant recipients. Pediatr Transplant 2005 : 9 : 780 787.
31. Jacqz-Aigrain E, Khan Shaghagi E, Baudouin V, et al. Pharmacokinetics and tolerance of mycophenolate mofetil in renal transplant children. Pediatr Nephrol 2000 : 14 : 95 99.
32. Garcia CD, Bittencourt VB, Tumelero A, et al. Enteric-coated mycophenolate sodium (EC-MPS) in pediatric renal transplantation - single center experience. Transplantation 2006 : 82 (Suppl 3 Abstract 1495.
33. Schwartz GJ, Haycock GB, Edelmann CM Jr, Spitzer A. A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine. Pediatrics 1976 : 58 : 259 263.